INSM vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Insmed Incorporated exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating significant fundamental instability. While the company shows explosive revenue growth of 152.6%, this is offset by extreme valuation metrics (Price/Sales of 55.10) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider activity—including significant sales by the CEO and COO—suggests a high-risk speculative profile rather than a value-driven investment.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
INSM vs MRK: Head-to-Head Comparison
This page compares Insmed Incorporated (INSM) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.